Follow this innovation
[ via 
] [?]
Biomarker for Assessing Efficacy and Utility of Cancer Therapeutics (Integrin Antagonists)
University of California System: University of California, San Diego Technology Transfer Office
posted on 01/18/2012
Indiscriminate delivery of drugs to entire patient populations is encumbered by such problems as reduced overall efficacy, added expense, failure to reach FDA endpoints, and inappropriate care for those patients who will not be responsive to a particular drug. Customized healthcare for individual patients is possible when one can pre-assess the probability that the targeted pathway is relevant for a given patient.
Suggested Uses
For patients who are candidates for treatment with drugs that act via the αvβ3 pathway, this invention provides methods for using an obligate, downstream phosphorylation event as a:
- Means of identifying individuals who will be responsive.
- Biomarker for disease progress.
- Surrogate marker for drug activity.
In sum, immunohistochemical staining of patient biopsies may serve as both a prognostic and predictive biomarker in determining tumor sensitivity and response to integrin antagonists pre- and post-treatment.
Advantages
In the near term, this approach may be applied to improve outcomes for:
- Drugs already in advanced clinical trials (e.g., Cilengitide) and MEDI-522.
- Achieving regulatory endpoints in clinical trials.
Detailed Description
Inventors at UC San Diego have validated methods for identifying individuals who will be responsive to drugs that act by events downstream of activation of the alpha v-beta3 (αvβ3) integrin pathway. By assessing a specific phosphorylation of a downstream peptide (C-RAF), this diagnostic can assess the efficacy of drugs that:
- Directly block activation of the αvβ3 pathway.
- Block ligand-αvβ3 interactions.
- Block specific phosphorylation of the C-RAF polypeptide.
This approach enables drug companies to improve their trials and, ultimately, can enable a clinician to customize the use of such cancer therapeutics to improve outcomes for cancer patients.
File Number: 22223
Disease: Cancer
Other Information:
Intellectual Property Info
Worldwide rights available; pending patents available under confidentiality.
| Copyright: | ©2012, The Regents of the University of California |
|---|
This innovation currently is not available for online licensing. Please contact University of California, San Diego Technology Transfer Office at University of California System: University of California, San Diego Technology Transfer Office for more information.
request more info
Case Manager:
 |
University of California, San Diego Technology Transfer Office
Innovations (747) |
|---|
ProfileFind more innovations
